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ABSTRACT
Trichosanthin (TCS) is a type I ribosome-inactivat-
ing protein that inactivates ribosome by enzymati-
cally depurinating the A4324 at the a-sarcin/ricin loop
of 28S rRNA. We have shown in this and previous
studies that TCS interacts with human acidic
ribosomal proteins P0, P1 and P2, which constitute
the lateral stalk of eukaryotic ribosome. Deletion
mutagenesis showed that TCS interacts with the
C-terminal tail of P2, the sequences of which are
conserved in P0, P1 and P2. The P2-binding site on
TCS was mapped to the C-terminal domain by
chemical shift perturbation experiments. Scanning
charge-to-alanine mutagenesis has shown that
K173, R174 and K177 in the C-terminal domain of
TCS are involved in interacting with the P2, pre-
sumably through forming charge–charge interac-
tions to the conserved DDD motif at the C-terminal
tail of P2. A triple-alanine variant K173A/R174A/
K177A of TCS, which fails to bind P2 and ribosomal
stalk in vitro, was found to be 18-fold less active in
inhibiting translation in rabbit reticulocyte lysate,
suggesting that interaction with P-proteins is
required for full activity of TCS. In an analogy to
the role of stalk proteins in binding elongation
factors, we propose that interaction with acidic
ribosomal stalk proteins help TCS to locate its RNA
substrate.
INTRODUCTION
Trichosanthin (TCS) is a type I ribosome-inactivating
protein (RIP) isolated from the root tuber of
Trichosanthes kirilowii. It is used clinically to treat
hydatidiform moles, trophoblastic carcinomas, ectopic
pregnancies and to terminate early and mid-trimester
pregnancies (1). TCS, like its homolog ricin A-chain,
inactivates ribosome through its RNA N-glycosidase
activity that depurinates an invariant adenine residue,
A4324 (numbering according to the rat sequence), in the
conserved a-sarcin/ricin loop (SRL) of 28S rRNA in
eukaryotic ribosomes (2–6). Such modiﬁcation prevents
binding of elongation factors to the SRL, and leads to the
arrest of protein synthesis (7,8).
The crystal structure of TCS (9) reveals that the protein
consists of two domains: a large N-terminal domain
(residues 1–172) consists of six alpha-helices, a six-
stranded mixed beta-sheet and a two-stranded anti-
parallel sheet, and a small C-terminal domain (residues
182–247), contains an anti-parallel beta-sheet and an
alpha-helix with a bend in the middle. The two domains
are connected by a loop (residues 173–181) rich in basic
residues (K173, R174 and K177). The active site of TCS
is located at the cleft between the N-terminal and the
C-terminal domains.
Although RIP is able to cleave naked rRNA, its kcat is
105-fold slower than that for rRNA within an intact
ribosome (6). This ﬁnding strongly suggests that riboso-
mal proteins are involved in rendering the rRNA
susceptible to inactivation by RIP. However, reports on
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the interaction between RIP and ribosomal proteins are
scarce. In an early study, ricin A-chain was cross-linked to
ribosomal proteins L9 and L10e (P0) of mammalian
ribosome (10). Pokeweed antiviral protein, another type I
RIP, was found to interact with yeast ribosomal protein
L3 (11,12). Based on a yeast two-hybrid screening and
conﬁrmed by in vitro pull-down assay, we have recently
shown that TCS interacts with acidic ribosomal proteins
P0 and P1 (13). In eukaryotic ribosomes, P0, P1 and P2
form a pentameric P-complex P0(P1)2(P2)2, which con-
stitutes the ribosomal stalk (14). P-complex docks on
the ribosome through the interaction with 28S rRNA,
and forms the GTPase-associated centre for binding
of elongation factors during protein synthesis (15,16).
The P-complex determines the speciﬁcity of ribosomes
for eukaryotic elongation factors. For example, swapping
the prokaryotic stalk proteins (L10 L7/124) with
P-complex changes the speciﬁcity of E. coli ribosomes to
use eukaryotic elongation factors for translation (17,18).
Cryo-electron microscopy map shows that the ribosomal
stalk extends outwards from the ribosome, and may play
a role in fetching the elongation factors from the cytosol
to the GTPase-associated centre of ribosome (19).
All ribosomal stalk proteins, P0, P1 and P2, possess a
conserved amino acid sequence rich in acidic residues in
their C-termini (14). Monoclonal antibody against this
consensus sequence can block the binding of elongation
factors to the P-complex and the ribosome-dependent
GTPase activities in protein synthesis in vitro (20). Given
the sequence similarity of the C-termini of P-proteins,
we hypothesize that TCS may bind P2 as well.
In this study, we ﬁrst demonstrate by in vitro pull-down
assay that TCS can bind P2. Deletion mutagenesis has
shown that TCS interacts with the conserved C-terminal
tail of P2, which explains why TCS can interact with all
acidic ribosomal proteins. The P2-binding site on TCS was
mapped by chemical shift perturbation to the C-terminal
domain of TCS. Charge-to-alanine scanning mutagenesis
has identiﬁed three basic residues, K173, R174 and K177,
that are involved in binding P2, presumably forming salt
bridges to conserved acidic residues of P2. We have found
that triple-alanine substitutions at positions 173, 174 and
177, which abolished the interaction with P2 and
with ribosomal stalk, resulted in a TCS variant with
about 18-fold less active in inhibiting a rabbit reticulocyte
protein synthesis system. Based on our results, the role of
interaction with P-proteins in the ribosome-inactivating
activity of TCS is discussed.
MATERIALS AND METHODS
Cloning and site-directed mutagenesis
TCS variants. E123A, K173A, R174A, D176A, K177A,
E189A, K197A, E210A, R222A, D229A, R243A and
K173A/R174A/K177A were created by polymerase chain
reaction (PCR) using mutagenic primers and were
subcloned to pET3d (Novagen). Expression and puriﬁca-
tion of TCS mutants were performed as described for
wild-type TCS (21).
P2 and its variants. The gene encoding P2 was ampliﬁed
by PCR (forward primer: 50 CAC GCC CAT GGC GAT
GCG CTA CGT CGC CTC C 30; reverse primer: 50 CAC
AGG GAT CCT AGT CAA AGA CAC CAA ATC C 30,
with underlined NcoI and BamHI sites, respectively)
from the human HTLV-transformed cDNA library. P2
C-terminal deletion mutants, P2C1, P2C2, P2C3,
P2C4, P2C5, P2C17, P2C28, P2C46 and
P2 DDD(106–108)AAA were created by PCR using
mutagenic primers and were subcloned to pET3d. To
create MBP-C7, MBP-C11, MBP-C14 and MBP-C17,
synthetic double-stranded oligonucleotides encoding the
last 7, 11, 14 and 17 residues of P2 were subcloned to an
in-house pRSETA-MBP vector, in which the poly-
histidine tag of pRSETA (Invitrogen) was replaced by
maltose-binding protein. To create MBP-C29 and MBP-
C36, DNA fragment encoding the last 29 and 36 residues
of P2 were obtained by PCR and were subcloned to the
pRSETA-MBP vector.
Preparation of protein samples
Proteins were expressed in E. coli strain C41(DE3) (22) or
BL21(DE3, pLysS) (Novagen) in M9 minimal medium
(6 g/l Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl, 2mM
MgSO4, 0.1mM CaCl2, 1mM thiamine-HCl) or M9ZB
medium (1 g/l of NH4Cl, 3 g/l of KH2PO4, 6 g/l of
Na2HPO4, 5 g/l of NaCl, 10 g/l of bacto-tryptone, 4 g/l
of glucose, 1mM MgSO4) containing the appropriate
antibiotics (50 mg/ml of chloramphenicol and/or 100 mg/l
of ampicillin). To prepare 15N-, 13C-, 2H-labelled NMR
sample, TCS was expressed in M9 medium prepared
in D2O containing 1 g/l
15NH4Cl and/or 2 g/l
13C-glucose.
Bacterial cells were grown in 378C until OD600 reached
0.4–0.8, when the expression was induced by
0.4mM (IPTG). The cells were harvested after overnight
culture at 378C by centrifugation at 3700 g at 48C
for 10min.
To purify TCS, cell lysate was loaded to a CM-
Sepharose (Amersham) column pre-equilibrated with
buﬀer A (20mM phosphate buﬀer, pH 6.5), and eluted
using a gradient of 0–0.5M NaCl in buﬀer A over 240ml.
Fractions containing TCS were pooled and dialysed
against buﬀer A, and loaded to a HiTrapTM SP column
(Amersham). The protein was eluted using a gradient of
0–0.3M NaCl in buﬀer A over 240ml. To purify P2,
P2C1, P2C2, P2C3, P2C4, P2C5 and P2
DDD(106–108)AAA, cell lysate was loaded to a DEAE-
Sepharose (Amersham) column pre-equilibrated with
buﬀer A at pH 7.8, and was eluted using a linear gradient
of 0–0.5M NaCl in buﬀer A over 240ml. Fractions were
pooled and dialysed against 20mM Tris/HCl, 1.5M NaCl
at pH 7.8 and then loaded to a 5ml HiTrapTM Phenyl HP
column (Amersham). P2 and its variants were collected
in the ﬂow-through, dialysed against buﬀer A, and
loaded to a 5ml HiTrapTM Q anion-exchange column
pre-equilibrated with buﬀer A at pH 7.8. The proteins
were eluted by a NaCl gradient of 0–0.3M in 300ml
of buﬀer A. To purify P2C17, P2C28 and P2C46,
protein fractions from the DEAE-Sepharose column were
concentrated to 5ml before loading to a HiLoadTM 26/60
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Superdex 75 column (Amersham) pre-equilibrated
with 20mM Tris/HCl, 0.2M NaCl at pH 8.5. Fractions
containing the P2 variants were pooled, dialysed
against buﬀer A at pH 8.5, and then loaded to a 5ml
HiTrapTM ANX or Q anion exchange column. A gradient
of 0–0.2M NaCl over 200ml was used to elute
the proteins.
NMR spectroscopy
All NMR experiments were carried out using a 1mM
protein sample containing 5% D2O in a four-channel
Varian Unity INOVA 750-MHz spectrometer with
z-axis pulsed-ﬁeld gradient capabilities for sensitivity
enhancement and water suppression at 303K. Backbone
resonance assignment of TCS was achieved by the
approach of triple resonance experiments. HNCACB
(23), HN(CO)CACB, HNCA and HN(CO)CA (24) were
acquired on a 15N, 13C, 2H triply labelled sample.
The assignment was conﬁrmed by short-range nuclear
Overhauser enhancements based on NOESY-HSQC
(100ms mixing time) and TOCSY-HSQC experiments
(25) acquired on a 15N-labelled sample. Data were
processed using the software NMRPipe (26), and the
spectra analysed by NMRView (27). Chemical shifts on
the 13C, and 15N dimensions were referenced using an
indirect method using the water resonances as an internal
reference (28,29).
Chemical shift perturbation
Unlabelled P2 (1.5mM sample in 20mM Tris/HCl,
pH 7.8) was titrated stepwise into 350 ml of 1.1mM
15N-labelled TCS. The protein concentrations at ﬁve
titration points were 0, 0.26, 0.44, 0.57 and 0.68mM for
P2, and 1.1, 0.92, 0.78, 0.68 and 0.60mM for TCS,
respectively. At each titration point, a 1H, 15N correlation
spectrum of TCS was recorded. All spectra were processed
by NMRPipe and analysed by NMRView. The changes in
1H and 15N chemical shifts of backbone amide of TCS
upon interactions with P2 were followed.
In vitro pull-down assay
TCS or P2 was coupled to NHS-activated Sepharose
(Amersham) according to the procedures recommended
by the manufacturer. To test if P2 and its variants interact
with TCS, 50 mM of protein samples were loaded to the
TCS-coupled NHS column pre-equilibrated with binding
buﬀer (20mM Tris/HCl, 10mM NaCl, pH 8.0). After
washing extensively with the binding buﬀer, the protein
was eluted with 0.1M glycine, 0.5M NaCl, pH 3.0 or
20mM Tris/HCl, 1M NaCl, pH 8.0. To test if TCS and its
variants interact with P2, 250 ml of 0.5mg/ml of protein
sample was loaded to a P2-coupled NHS-Sepharose
(200ml resin) pre-equilibrated with the binding buﬀer.
After washing the column extensively with the binding
buﬀer, the protein was eluted with 20mM Tris/HCl, 1M
NaCl, pH 8.0.
Interactions between TCS and ribosomes
Pull-down assay. 80S ribosome was prepared from rat
liver as described (30). Here, 150 ml of rat ribosome
(OD260¼ 23.5) was loaded to a TCS-coupled NHS column
pre-equilibrated with 20mM Tris/HCl, 150mM NaCl,
5mM EDTA, 1% NP-40, 0.1% SDS, pH 8.0. After
extensive washing, bound proteins were eluted with
20mM Tris/HCl, 1M NaCl, pH 8.0, and detected by
western blotting using anti-P antibody.
Cross-linking. Here, 3 mg of TCS was added to 105 ml of rat
ribosome (OD260¼ 23.5) in 150mM potassium phosphate
buﬀer at pH 7.4. After incubation at room temperature for
20min, 0.41 mg of disuccinimidyl suberate (DSS; Pierce)
was added to the reaction mixture. Cross-linking reaction
was allowed to occur for 30min at room temperature
before it was quenched by 50mM Tris buﬀer at pH 7.5.
The cross-linked product was then analysed by western
blotting using anti-P and rabbit anti-TCS antibodies.
Translation inhibition assay
In vitro translation was performed as described (31) using
nuclease-untreated rabbit reticulocyte lysate, which uses
endogenous mRNA template for protein synthesis.
In brief, 3.7 pM to 370 nM of TCS or 75 mg/ml of bovine
serum albumin (BSA) was added to the rabbit reticulocyte
lysate supplemented with 10mM creatine phosphate,
35 mg/ml creatine kinase, 67mM KCl, 0.33mM MgCl2,
35 mg/ml haemin and 5 nCi [3H]-leucine (PerkinElmer).
After incubation at 308C for 30min, the mixture was
decolourized by NaOH/H2O2. The [
3H]-labelled trans-
lation product was then precipitated by 25% (v/v)
trichloroacetic acid, collected by ﬁltration, and quantiﬁed
by liquid scintillation counting. The amount of [3H]-leucine
incorporation relative to that of the BSA control was
plotted as a function of TCS concentration, and the values
of IC50 were determined by ﬁtting the data to a four-
parameter logistic equation using non-linear regression.
Depurination assay
Speciﬁc depurination of A-4324 of 28S rRNA by TCS
was detected by aniline treatment as described (31) with
minor modiﬁcation. In brief, 10 nM TCS and its variants
were incubated with rabbit reticulocyte lysate at 378C for
30min. RNA was extracted by TRIzol reagent
(Invitrogen), treated with acidic aniline at 608C for
5min, and precipitated by ethanol. The RNA pellet was
dissolved in water, and analysed by agarose gel electro-
phoresis in TAE buﬀer.
Molecular modelling of TCS–rRNA complex
The coordinates of the SRL were obtained from the
crystal structure of the large ribosomal subunit from
Haloarcula marismortui (PDB code: 1FFK) (32), and the
coordinates of TCS were obtained from the crystal
structure of TCS complexed with adenine (PDB code:
1MRJ). The adenine ring of A2697 (analogous to A4324 in
rat 28S rRNA) was ﬂipped to the syn conformation (as in
the conformation of formycin monophosphate in the
active site of ricin, PDB code: 1FMP), and was positioned
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to the adenine bound to the active site of TCS. The SRL
was docked manually to the active site of TCS, with the
guidance of a published model of pokeweed antiviral
protein–SRL complex (33,34). The model was energy
minimized using the program CNS (35). During the
minimization, only the loop residues, G2696–A2699, were
allowed to be ﬂexible, while other parts of SRL and TCS
were restrained as a rigid body.
RESULTS
TCS interacts with acidic ribosomal stalk protein P2
Based on yeast two-hybrid screening and conﬁrmed by
in vitro pull-down assay, our group has previously
demonstrated that TCS interacts with human acidic
ribosomal proteins P0 and P1 (13). Since P2 belongs to
the same family of acidic ribosomal protein, we hypothe-
size that P2 can also interact with TCS. The interaction
between TCS and P2 was investigated by in vitro
pull-down assay. As shown in Figure 1a, P2 bound to
the TCS-coupled NHS-Sepharose (lane 1), while no
retention of the BSA control was observed (lane 2). The
binding between TCS and P2 was further conﬁrmed
by loading TCS to P2-coupled NHS-Sepharose. It was
found that TCS, but not the BSA control, bound to the
P2-coupled Sepharose (Figure 1b, lanes 1 and 2). Non-
speciﬁc binding of TCS and P2 to the Sepharose column
was ruled out by loading TCS or P2 to an uncoupled
NHS-Sepharose (Figure 1a and b, lane 3).
Systematic deletion studies showed that TCS interacts
with the conserved C-terminal tail of P2
Sequence alignment of P0, P1 and P2 reveals that the three
acidic ribosomal stalk proteins share a conserved
C-terminal region rich in acidic residues (Figure 2a
and b). Since TCS interacts with all acidic ribosomal
proteins, we hypothesize that the conserved C-terminal
region of P2 is involved in binding TCS. To test this
hypothesis, we created systematic deletion mutants of P2
(P2C1, P2C2, P2C3, P2C4, P2C5, P2C17,
P2C28 and P2C46, where the number after the 
sign indicates the number of residues deleted from the
C-terminus). The interaction between TCS and these
deletion mutants of P2 was checked by in vitro pull-down
assay (Figure 2c and d). Conﬁrming the role of C-terminus
of P2 in binding TCS, our data showed that deletion of
two or more residues at the C-terminus of P2 would
seriously compromise or completely abolish the interac-
tion between TCS and P2 (Figure 2c and d).
Although the acidic ribosomal proteins share a
conserved C-terminal region, their sequences diﬀer in
their N-terminal domains. It is likely that the C-terminal
region of P2 alone is responsible for binding TCS. To test
this hypothesis, we fused the last 7, 11, 14, 17, 29, 36
residues of P2 to the maltose binding protein (MBP)
to create MBP-C7, MBP-C11, MBP-C14, MBP-C17,
MBP-C29 and MBP-C36 fusion proteins, and tested the
interaction between TCS and these fusion proteins by
in vitro pull-down assay. Our data showed that the MBP
fusion proteins with the last eleven or longer residues of
P2 were retained on TCS-coupled Sepharose, while MBP-
C7 failed to bind TCS (Figure 2e). These data suggested
that the last eleven residues of P2 are suﬃcient for
interacting with TCS.
The conserved DDDmotif at the C-terminal tail of
P2 interacts with TCS
As TCS interacted with the C11 peptide (SDDD
MGFGLFD) but not the C7 peptide (MGFGLFD) of
Figure 1. TCS interacts with P2 in vitro. (a) P2 was loaded to TCS-coupled NHS-activated column pre-equilibrated with binding buﬀer. After
extensive washing, P2 was eluted with 1M NaCl (lane 1). (b) TCS was loaded to P2-coupled NHS-activated column pre-equilibrated with binding
buﬀer. After extensive washing, TCS was eluted with 1M NaCl (lane 1). The eluted proteins were analysed by SDS-PAGE with Coomassie blue
staining (upper panel), and the identity of P2 and TCS was conﬁrmed by western blot (lower panel) using anti-P and anti-TCS antibody, respectively.
In both cases, two negative controls were carried out. First, BSA was loaded to the TCS- or P2- coupled column and no BSA was found in the
elution (lane 2). Second, P2 or TCS were loaded to uncoupled NHS-Sepharose, and no P2 or TCS were found in the elution (lane 3).
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P2 (Figure 2a and f), it is likely that the conserved DDD
motif of P2 interacts with TCS via formation of charge–
charge interactions. To test this hypothesis, the DDD
motif in P2 was substituted with alanine to create a variant
of P2 DDD(106–108)AAA. In vitro pull-down assay
showed that the triple-alanine substitution abolished the
interaction between P2 and TCS (Figure 2c and d). When
the last eleven residues (SAAAMGFGLFD) of the triple-
alanine variant of P2 were fused to the MBP, the resulting
MBP-C11 DDD(106–108)AAA also failed to interact
Figure 2. TCS interacts with the conserved C-terminal region of P2. (a) The primary sequence of human P2 is aligned with the C-terminal residues
of other acidic ribosomal stalk proteins P0 and P1. The last 17 residues of P0, P1 and P2 are highly conserved and are highlighted in the ﬁgure.
(b) The last 11 residues of P-proteins are highly conserved. The sequences of the C-terminal residues of P-proteins from the SWISS-PROT database
were aligned by the program CLUSTAL W (41), and are shown in a sequence logo representation (42) generated by a web-based program WebLogo
(43). Sequences are numbered according to the human P2 sequence. (c and d) The interaction between C-terminal deletion mutants of P2 and TCS
was checked by in vitro pull-down assay. In (c), deletion mutants of P2 were loaded to TCS-coupled NHS-Sepharose; while in (d), TCS was loaded to
NHS-Sepharose coupled with P2 deletion mutants. The elution fractions from the pull-down assay were analysed by 15% SDS-PAGE stained with
Coomassie blue. The presence of P2 mutants in (c) or TCS in (d) in the elution fractions indicates positive interaction between TCS and the P2
deletion mutants. In both (c and d), wild-type P2 was included as a positive control. (e) In vitro pull-down assay on the interaction between TCS and
C-terminal tail of P2. The last 7, 11, 14, 17, 29, 36 residues of P2 were fused to MBP to create MBP-C7, MBP-C11, MBP-C14, MBP-C17, MBP-C29
and MBP-C36 fusion proteins. Bacterial lysates containing these fusion proteins were loaded to a TCS-coupled NHS-Sepharose column. The elution
fractions from the pull-down assay were analysed by 15% SDS-PAGE stained with Coomassie blue. Our data indicate that MBP-C11, MBP-C14,
MBP-C17, MBP-C29, MBP-C36 fusion proteins, but not the MBP control, MBP-C7 and MBP-C11 DDD(106–108)AAA, were retained by the TCS-
coupled column. The results of the in vitro pull-down assay are summarized in (f).
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with TCS (Figure 2e). These data suggest that the negative
charges of the DDD motif play a crucial role in binding
TCS.
Chemical shift perturbation experiments mapped the
P2-binding site to the C-terminal domain of TCS
As a ﬁrst step towards mapping the P2-binding site on
TCS by chemical shift perturbation, we have assigned the
backbone resonances of TCS based on the triple resonance
experiments HNCA, HN(CO)CA, HN(CO)CACB and
HNCACB, which established links between residues via
their Ca and Cb chemical shifts. Deuterated NMR samples
of TCS, a 247-residue protein, were used to improve the
quality of the spectra. Short-ranging nuclear Overhauser
enhancements from 1H,15N NOESY-HSQC were used to
resolve ambiguity and to conﬁrm the assignment. Of 238
backbone amide resonances, 196 were assigned, which
include most of the surface residues of TCS, and allow
mapping the P2-binding site by chemical shift perturba-
tion experiments.
Unlabelled P2 was titrated to 15N-labelled TCS sample,
and the 1H and 15N chemical shifts of backbone amide
resonances were followed. It was observed that a subset of
peaks, as indicated in Figure 3a, moved gradually from
the positions in the free form (black contours) to new
positions (red contours) upon addition of P2 until the
molar ratio of TCS:P2 reach 1. As shown in Figure 3b,
residues with large amide chemical shift changes are
predominantly clustered in the C-terminal domain
(173–247) of TCS. In particular, large changes in chemical
shift changes (40.075 ppm on the 1H dimension or
40.5 ppm on the 15N dimension) were observed for
residues 69, 123, 174, 175, 182, 187, 190, 191, 215, 216,
221, 222, 223, 225, 233 and 236—all of them are
localized in or near the C-terminal domain of TCS
(Figure 3c).
Scanning charge-to-alanine mutagenesis showed that K173,
R174 and K177 are involved in TCS–P2 interaction
Chemical shift perturbation experiments have identiﬁed
the C-terminal domain of TCS as the P2 interaction site.
Since TCS interacts with all P-proteins, which contain a
conserved C-terminal tail rich in charge residues (espe-
cially acidic residues), we anticipated that TCS may
interact with P2 via charge–charge interactions. To
identify which charge residues in the C-terminal domain
interact directly with P2, we have performed scanning
charge-to-alanine mutagenesis. There are 11 charge
residues in this region: E123, K173, R174, D176, K177,
E189, K197, E210, R222, D229 and R243 (Figure 3c).
These residues were substituted by alanine to create 11
variants of TCS. To see if these charge-to-alanine
substitutions would aﬀect the TCS–P2 binding, TCS or
its variants were loaded to the P2-coupled NHS-Sepharose
(Figure 4). The detection of unbound K173A, R174A and
K177A variants in the wash fractions (Figure 4b–d)
suggests that charge-to-alanine substitution at these basic
residues may weaken the binding between TCS and P2. To
further investigate the role of K173, R174 and K177 in
TCS–P2 interaction, we have created a triple-alanine
variant (K173A/R174A/K177A) of TCS. In vitro pull-
down assay showed that this triple charge-to-alanine
substitution completely abolished the interaction between
TCS and P2 (Figure 4e).
Interaction between TCS and ribosomal stalk was reduced
by triple-alanine substitutions at K173, R174 and K177
positions
So far, we have shown that TCS interacts with the last
11 residues of P2. Since the C-terminal sequences of all
stalk proteins P0, P1 and P2 are highly conserved
(Figure 2a and b), it is likely that TCS interacts with the
ribosome via this acidic C-terminal tails of P-proteins.
If this is the case, the interactions between TCS and
ribosome will be adversely aﬀected if the three basic
residues (K173/R174/K177) involved in binding P2 were
substituted by alanine. To test this hypothesis, we have
loaded 80S rat ribosome to NHS-Sepharose coupled
with wild-type TCS or its triple-alanine variant (K173A/
R174A/K177A). Our data showed that wild-type TCS was
able to pull-down all acidic ribosomal proteins (P0, P1 and
P2) from rat ribosome, while the interaction between the
triple-alanine variant and ribosome was greatly reduced
(Figure 5a). These data are consistent with the conclusion
that TCS interacts with ribosome through the conserved
C-terminal tails of P-proteins.
Direct interaction between TCS and the ribosomal stalk
was further conﬁrmed by cross-linking experiments. TCS
or the triple-alanine variant was cross-linked with rat
ribosome using DSS, and the cross-linking between TCS
and P-proteins was identiﬁed by anti-P and anti-TCS
antibodies. Our data showed that wild-type TCS was able
to form a 66 kDa cross-linking product with rat
ribosome, which corresponds to the expected molecular
weight of TCS–P0 complex (Figure 5b, lane 2).
In contrast, no TCS–P-protein complex was observed
for the triple-alanine variant (K173A/R174A/K177A)
(Figure 5b, lane 5). Taken together, our data suggest
that TCS can interact directly to the ribosomal stalk, and
the triple-alanine substitution abolished such interaction.
It is noteworthy that no cross-linking product of
TCS with P1 or P2 was observed in our experiment.
We also noticed that the amount of P1 and P2 pull-down
by TCS from rat ribosome was less than that for P0
(Figure 5a). Unlike P0, which forms an integral part of
ribosome, P1 and P2 were also found as free proteins in
the cytoplasm. It was found that the cytoplasmic pool
of P1/P2 can exchange readily with those bound to the
ribosomal stalk (36). It is possible that the interaction
between TCS and P0 is stronger than that for P1 and P2 so
that TCS was preferentially cross-linked with P0 in the
stalk of rat ribosome.
Charge-to-alanine substitutions at K173, R174 and K177
weaken the inhibition of in vitro translation
Charge-to-alanine scanning mutagenesis has identiﬁed
three residues (K173, R174 and K177) that are directly
involved in TCS–P2 and TCS–ribosome interaction. To
see if alanine substitutions at these residue positions aﬀect
the ability of TCS to inhibit in vitro translation, we have
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measured the IC50 values (the concentration of TCS to
achieve 50% inhibition of protein synthesis in an in vitro
translation system) of TCS and its variants (Figure 6a).
The values of IC50 for wild-type TCS, K173A, R174A,
D176A, K177A and the triple-alanine variants were
0.027 0.001, 0.20 0.04, 0.16 0.02, 0.038 0.004,
0.09 0.01, 0.5 0.1nM, respectively. Single alanine sub-
stitutions K173A, R174A and K177A resulted in 7-, 6- and
3-fold increases in the values of IC50, suggesting that these
charge-to-alanine substitutions weaken the ability of
TCS to inhibit in vitro protein synthesis. The eﬀect of
charge-to-alanine substitution was accumulative—the
K173A/R174A/K177A triple-substitution resulted in
18-fold increase in the IC50 value. On the other hand,
D176A substitution, which did not aﬀect the TCS–P2
interaction, had no signiﬁcant eﬀect on the IC50. To test
Figure 3. P2-binding site on TCS was mapped to the C-terminal domain by chemical shift perturbation. (a) 1H–15N correlation spectra of TCS in the
absence (black contours) and in the presence (red contours) of equal molar ratio of P2 were compared, and (b) changes in chemical shifts,
ippm(HN) and ippm(N), of amide resonances of TCS were measured. Residues with ippm(HN) 40.075 ppm or ippm(N) 40.5 ppm are
indicated in (a) and (b), and colour-coded magenta in the stereo diagram of TCS in (c). These residues are localized in or near the C-terminal domain
(173–247, colour-coded green) of TCS. Scanning alanine mutagenesis was performed on all charge residues in the C-terminal domain and E123,
which are indicated in (c).
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if the charge-to-alanine substitutions abolish the
N-glycosidase activity of TCS, rabbit reticulocyte lysate
was incubated with TCS or its variants at a concentration
(10 nM) that is suﬃcient to achieve complete inhibition
of in vitro translation. Depurination assay showed that
all TCS variants tested were able to depurinate A4324 of
28S rRNA (Figure 6b). Taken together, our data suggest
that all TCS variants inactivate ribosomes through their
N-glycosidase activity, but they do diﬀer in their potency
in inhibiting in vitro protein synthesis.
DISCUSSION
TCS, a homolog of ricin A-chain, belongs to type I RIP.
TCS is an RNA N-glycosidase, the substrate of which is
the a-sarcin/ricin-loop (SRL) of eukaryotic 28S rRNA.
TCS inactivates ribosome by removing the adenine
base speciﬁcally at A4324, which abolishes binding of
elongation factors to the ribosome. Although RIP can
depurinate naked rRNA, the kcat value of such reaction
is 105-fold lower than that for rRNA in ribosome.
Figure 4. In vitro pull-down assay on TCS variants suggests that K173, R174 and K177 are involved in binding P2. TCS (a) or its variants
(b–m) were loaded to a P2-coupled NHS-Sepharose pre-equilibrated with binding buﬀer. Bound protein was eluted with 1M NaCl in 20mM
Tris/HCl buﬀer pH 8.0. Fractions containing unbound protein collected during washing (W) and bound protein collected during elution (E) were
analysed in 15% SDS-PAGE stained with Coomassie blue. As indicated by the presence of TCS in the wash fraction, substitution of alanine at K173,
R174 and K177 positions decreases the binding of TCS on P2-coupled column (b–d). Triple-alanine substitutions in these residue positions resulted
in a TCS variant (K173A/R174A/K177A) that was unable to bind P2 (e).
Figure 5. Interaction between TCS and ribosome was compromised by K173A/R174A/K177A triple-alanine substitutions. (a) Pull-down assay.
Rat ribosome was loaded to NHS-Sepharose coupled with TCS or its triple-alanine (K173A/R174A/K177A) variants. After extensive washing, the
bound proteins were eluted with 1M NaCl, and detected by western blot using anti-P antibody. Ribosomal proteins P0, P1 and P2 were pull-down
by wild-type TCS (lane 2), while the interaction between ribosome and the triple-alanine variants (lane 1) was greatly reduced to that similar to the
control (lane 3), in which the faint band of P0 was due to non-speciﬁc interactions between ribosome and the uncoupled resins. (b) Cross-linking
experiments. After rat ribosome was incubated with TCS or the triple-alanine variants in room temperature for 20min, DSS was added to induce
cross-linking between TCS and ribosomal proteins, and cross-linking product was detected by western blot using anti-P or anti-TCS antibodies.
A protein band at 66 kDa, corresponding to the size of TCS–P0 complex, was detected by both anti-P and anti-TCS antibodies when ribosome was
cross-linked with wild-type TCS (lane 2), but not with the triple-alanine variants (lane 5) and in other negative controls (lanes 1 and 4: without
addition of ribosome; lanes 3, 6 and 8: without addition of DSS; lanes 7 and 8: without addition of TCS or its variants).
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This ﬁnding strongly suggests that interaction between
RIP and ribosomal proteins is essential to achieve full
activity of RIP. Although all RIPs can inactivate
eukaryotic ribosomes, some RIPs, like pokeweed antiviral
protein, Mirabilis antiviral protein, and Shiga toxin, can
also inactivate prokaryotic ribosomes. The kingdom
speciﬁcity of ribosome substrate for some RIPs is likely
due to the interaction of RIP with ribosomal proteins.
In this study, we have demonstrated that TCS interacts
with acidic ribosomal stalk protein P2. Together with our
previous ﬁnding that TCS interacts with other acidic
ribosomal stalk proteins P0 and P1, TCS was shown
Figure 6. (a) Translation inhibition assay. The potency of TCS variants to inhibit in vitro translation was measured by adding 3.7 pM to 370 nM of
protein samples to nuclease-untreated rabbit reticulocyte lysate as described in the Materials and methods section. IC50, the concentration of TCS
required to achieve 50% inhibition, was determined by ﬁtting the data to a four-parameter logistic equation. The values of IC50 for WT (ﬁlled circle),
K173A (open square), R174A (open diamond), D176A (open triangle), K177A (open circle), and the triple-alanine variant (ﬁlled square) were
0.027 0.001, 0.20 0.04, 0.16 0.02, 0.038 0.004, 0.09 0.01, 0.5 0.1nM, respectively. (b) Depurination assay of TCS and its variants. After
incubation with 10 nM of TCS or its variants, RNA from the rabbit reticulocyte lysate was extracted, treated with aniline and analysed by
electrophoresis as described in the Materials and methods section. Depurination of 28S rRNA at A4324 was detected by the 450 bp R-fragments
(indicated by an arrow). Control lanes, in which RNA samples were not treated with aniline, are labelled with the ‘’ marks.
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to interact with all acidic P-proteins that constitute
the lateral stalk of the large 60S ribosomal subunit.
The ability of TCS to bind all P-proteins can be explained
by the systematic deletion study, which has mapped the
TCS-binding site to the conserved C-terminal tail of P2
(Figure 2). We have fused the last eleven residues of P2
to MBP, and found that the resulting MBP–C11 fusion
protein can interact with TCS (Figure 2e). Since the last
eleven residues of human P-proteins are highly conserved,
with the consensus sequence SDD/EDMGFGLFD
(Figure 2a), our data strongly suggest that TCS can interact
with all P-proteins via this consensus C-terminal tail.
Using chemical shift perturbation experiment, we have
located the P2-binding site to the C-terminal domain of
TCS (Figure 3). Our ﬁnding is consistent with a previous
study which showed that Saporin, another type I RIP,
interacts with yeast ribosome through the C-terminal
domain (37). Scanning charge-to-alanine mutagenesis has
identiﬁed three basic residues, K173, R174 and K177, that
are involved in P2 binding (Figure 4). Electrostatics
calculation showed that the surface of TCS near these
basic residues is strongly positively charged (Figure 7a),
and it is likely that the acidic C-terminal tail of P2 binds to
this region of TCS via charge–charge interactions.
In agreement, we have shown that TCS interacts with
the last eleven residues (SDDDMGFGLFD) of P2
(Figure 2a and e), and substitution of the three aspartate
residues in the conserved DDD motif of the P2C-terminal
tail abolished the interaction between TCS and P2
(Figure 2c–f). This ﬁnding, together with our results
that the triple-alanine variant (K173A/R174A/K177A) of
TCS was unable to bind P2, strongly suggests that these
basic residues form charge–charge interaction with the
consensus DDD motif of P2.
On the other hand, electrostatic interaction is unlikely
to be the only factor contributing to TCS–P2 binding.
For example, deletion of the last Asp residue at
P2C-terminus (P2C1) did not aﬀect the TCS–P2
interaction. However, further deletion of non-polar
residues (FGLF, P2C2–P2C5) seriously compromised
the TCS–P2 binding. There is an exposed hydrophobic
pocket at the C-terminal domain of TCS, which is
constituted by F166, A184, L188, L215, I225 and V232
(Figure 7a). It is noteworthy that residues near this
hydrophobic pocket were found to have larger chemical
shift changes upon addition of P2 (Figures 3b and c,
and 7a). It is likely that this hydrophobic pocket interacts
with the non-polar residues at the C-terminal tail of P2.
Taken together, the in vitro binding data on TCS and
P2 imply that TCS can bind to the stalk of ribosome
through interacting with the conserved C-terminal tail of
P-proteins. This hypothesis was supported by the fact that
TCS can be cross-linked to P0 in rat ribosome, and such
cross-linking was abolished in the triple-alanine variant
(K173A/R174A/K177A) of TCS (Figure 5b). Moreover,
the interaction between the triple-alanine variant and
ribosome was also greatly compromised (Figure 5a).
These ﬁndings suggest that the three basic residues of
TCS form charge–charge interactions with the conserved
acidic residues of P-proteins in ribosomal stalk. Our
observation that TCS can bind to the ribosomal stalk is
consistent with a previous study which showed that ricin
A-chain, a homolog of TCS, was cross-linked to P0 (L10e)
of ribosome from human lung carcinoma cells (10).
Ribosomal stalk, which is constituted by acidic
P-proteins in eukaryotic ribosomes, was shown to play
an important role in binding elongation factors. For
example, EF2 binding can be blocked by anti-P-protein
antibodies (20). Replacement of prokaryotic stalk proteins
with P-proteins changed the elongation-factor-speciﬁcity
of E. coli ribosome from prokaryotic EF-G to eukaryotic
EF2 (17,18). Recently, cryo-electron microscopy of
EF2–sordarin–ribosome complex demonstrated that EF2
directly binds to the SRL and interacts with P-proteins
(38). In an 11.7-A˚ cryo-electron microscopy map, residues
176–191 in domain I of EF2 was shown to be in contact
with P-proteins (Figure 7b).
To compare the P-protein-binding site on TCS and on
EF2, we have docked TCS to the SRL substrate as
described in the Materials and methods section
(Figure 7c), based on the predicted models of ricin–SRL
(39) and pokeweed antiviral protein–SRL (33,34). As both
TCS and EF2 bind to the SRL, it is anticipated that TCS
will occupy the EF2-binding site on ribosome.
Superimposition of TCS–SRL and EF2–SRL models
reveals that the P-protein-binding site of TCS is close in
space to that of EF2 (Figure 7d), which suggests that upon
TCS binding to the ribosome, the P-proteins are able to
physically reach the P-protein-binding sites on TCS.
Our results support the conclusion that interaction with
P-protein is required for full activity of TCS. We showed
that alanine substitutions at K173, R174 and K177
positions compromise P2 protein binding and reduce the
in vitro translation inhibition of TCS. In particular, triple-
alanine substitutions of these basic residues weaken the
interactions between TCS and ribosomal stalk (Figure 5),
and resulted in18-fold increases in IC50 value (Figure 6a).
As these residues are far away from the SRL-binding site
of TCS, the decrease in translation inhibition is likely
caused by weakening of P-protein interaction but not
by direct perturbation in RNA binding.
There are several possibilities of how TCS–P-protein
interaction may play a role in ribosome-inactivating
activity. First, interaction with the P-proteins may guide
TCS to locate the SRL. It has been proposed that
the ﬂexible stalk proteins, which are protruding out of
the ribosome, increase the association rate of elongation
factors by grabbing them in the solution and fetch them to
the binding site on ribosome (40). Similarly, binding to the
stalk proteins (P0/P1/P2) anchors TCS to a location of
ribosome near the SRL substrate, and allows TCS to ﬁnd
its SRL substrate more eﬃciently. Moreover, the ability of
TCS to interact with multiple copies of C-terminal tails of
the stalk proteins (P0/P1/P2) may increase the association
rate between TCS and ribosome. Second, interaction with
P-proteins may induce conformational changes on TCS,
which will increase its enzymatic activity. Alternatively,
binding of TCS to the ribosome may also change the
conformation of ribosome, making the SRL more
susceptible to depurination by TCS. Third, binding of
TCS to P-proteins may hinder the association of elonga-
tion factors to the ribosome. TCS and all RIPs,
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Figure 7. Comparison of P-protein-binding sites on eEF2 and TCS. (a) Putative P2-binding surface of TCS. The electrostatic calculation was
performed using the program APBS (44) and visualized by PyMOL (45), where positive and negative potential surface is colour-coded blue and red,
respectively, at 10 kT. K173, R174 and K177 contribute to a strongly positive-charged surface which may interact with the DDD motif of P2.
The arrow indicates the location of the hydrophobic pocket constituted by F166, A184, L188, L215, I225 and V232. A ribbon representation
of TCS, with the C-terminal domain colour-coded green, is shown on the right panel. Residues with large changes in amide chemical shifts
(as in Figure 3c) are colour-coded magenta. (b) The structure of eEF2–SRL complex was derived from an 11.7-A˚ cryo-electron microscopy map of
the 80S ribosome complexed with eEF2 and sordarin (38) (PDB code 1S1H and 1S1I). Residues Q176-T191 (colour-coded dark green) of eEF2 were
found to be in contact with P-proteins in the cryo-electron microscopy map (38). (c) The model of TCS–SRL complex was obtained as described in
the Materials and methods section. The C-terminal domain of TCS is colour-coded magenta. (d) The model of TCS–SRL complex is superimposed
onto the structure of eEF2–SRL complex. The three basic residues (K173, R174 and K177) that were found to be involved in binding P2 are
shown in ball-and-stick representation in (c) and (d). Noteworthy, the P-protein-binding site (dark green) on eEF2 is in close proximity to the
P-protein-binding site (magenta) of TCS.
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which target the SRL, occupy the elongation-factor-
binding site on ribosome. Interaction with P-proteins
may help TCS to compete with other elongation factors,
and block the access of these factors to the SRL. For
example, it has been shown that monoclonal antibody that
binds speciﬁcally to the C-terminal of P-proteins inhibit
protein synthesis by blocking access of elongation factors
to the ribosomal stalk (20). Work is underway to clarify
some of these possibilities.
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